Current issues of RNAi therapeutics delivery and development

Area of Science:

• Biotechnology
• Molecular Medicine
• Drug Delivery

Background:

• RNA interference (RNAi) discovery has spurred development of therapeutics for significant diseases like TTR amyloidosis, HBV, and cancers.
• Despite progress, RNAi therapeutic perception fluctuates due to scientific, regulatory, and market factors.

Purpose of the Study:

• To provide an update on RNAi therapeutics development, focusing on current delivery capabilities and future challenges.
• To highlight the potential of RNAi delivery to expand therapeutic opportunities beyond the liver.

Main Methods:

• Review of current RNAi delivery technologies, including lipid nanoparticles (LNPs), GalNAc-siRNA conjugates, and Dynamic PolyConjugates (DPCs).
• Assessment of demonstrated gene knockdown efficacy in preclinical models and clinical trials.
• Discussion of challenges and strategies for improving RNAi delivery to various cell types and tissues.

Main Results:

• RNAi therapeutics utilizing LNPs, GalNAc-siRNA, and DPCs show profound gene knockdown in the liver, addressing a significant therapeutic and commercial opportunity.
• Current technologies show potential for treating solid tumors, eye diseases, respiratory conditions, and certain blood, vascular, and kidney disorders.
• Delivery limitations, including biodistribution and cellular uptake, restrict broader applications, necessitating further innovation.

Conclusions:

• RNAi therapeutics have the potential to treat a wide range of diseases, especially those involving the liver, with existing delivery methods.
• Overcoming delivery challenges such as vascular escape, tissue penetration, and cellular uptake is crucial for expanding RNAi applications.
• Continued research and investment in RNAi delivery technologies are essential to realize the full therapeutic potential of RNAi.